Novo Nordisk A/S (NYSE:NVO) Upgraded to Hold at Zacks Research

Key Points

• Zacks Research upgraded Novo Nordisk from "strong sell" to "hold," and MarketBeat shows a consensus analyst rating of Hold with an average price target of $49.93.
• The company recently beat quarterly estimates (EPS $1.01 vs. $0.90; revenue $12.43B vs. $11.97B) and trades around $38.82 with a market cap of about $173.3B and a 1‑year range of $35.85–$82.57.
• Key near‑term dynamics include an FDA warning over semaglutide post‑marketing reporting and an investor probe that raise regulatory/legal risk, offset by a Hims & Hers telehealth deal as a potential volume catalyst amid strong competition from Eli Lilly.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) was upgraded by equities research analysts at Zacks Research from a "strong sell" rating to a "hold" rating in a report issued on Tuesday,Zacks.com reports.

Other equities analysts also recently issued research reports about the stock. Deutsche Bank Aktiengesellschaft downgraded shares of Novo Nordisk A/S from a "buy" rating to a "hold" rating in a research note on Monday, February 23rd. CICC Research started coverage on Novo Nordisk A/S in a report on Friday, January 9th. They issued an "outperform" rating and a $73.50 target price for the company. Jefferies Financial Group upgraded Novo Nordisk A/S from an "underperform" rating to a "hold" rating in a report on Thursday, February 12th. The Goldman Sachs Group reaffirmed a "neutral" rating and issued a $41.00 price target (down from $63.00) on shares of Novo Nordisk A/S in a research report on Monday, March 2nd. Finally, Nordea Equity Research cut Novo Nordisk A/S to a "hold" rating in a research note on Tuesday, February 24th. Four research analysts have rated the stock with a Buy rating and nineteen have issued a Hold rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of "Hold" and a consensus target price of $49.93.

Novo Nordisk A/S Stock Up 0.2%

Shares of NVO opened at $38.82 on Tuesday. The company's 50-day simple moving average is $50.69 and its 200-day simple moving average is $52.02. The company has a debt-to-equity ratio of 0.61, a quick ratio of 0.57 and a current ratio of 0.80. Novo Nordisk A/S has a 1 year low of $35.85 and a 1 year high of $82.57. The stock has a market capitalization of $173.31 billion, a PE ratio of 11.19 and a beta of 0.73.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last announced its quarterly earnings data on Tuesday, February 3rd. The company reported $1.01 earnings per share for the quarter, beating analysts' consensus estimates of $0.90 by $0.11. The firm had revenue of $12.43 billion during the quarter, compared to analysts' expectations of $11.97 billion. Novo Nordisk A/S had a net margin of 33.03% and a return on equity of 68.91%. Analysts forecast that Novo Nordisk A/S will post 3.84 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Novo Nordisk A/S

Several hedge funds have recently added to or reduced their stakes in the stock. True Wealth Design LLC grew its position in shares of Novo Nordisk A/S by 209.8% in the 3rd quarter. True Wealth Design LLC now owns 443 shares of the company's stock valued at $25,000 after buying an additional 300 shares during the last quarter. Guerra Advisors Inc purchased a new stake in Novo Nordisk A/S in the third quarter valued at $25,000. Godfrey Financial Associates Inc. acquired a new position in Novo Nordisk A/S in the fourth quarter valued at $25,000. Strengthening Families & Communities LLC purchased a new position in shares of Novo Nordisk A/S during the third quarter worth about $30,000. Finally, WealthCollab LLC grew its holdings in shares of Novo Nordisk A/S by 93.5% during the fourth quarter. WealthCollab LLC now owns 538 shares of the company's stock worth $27,000 after purchasing an additional 260 shares during the last quarter. 11.54% of the stock is currently owned by hedge funds and other institutional investors.

Key Stories Impacting Novo Nordisk A/S

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Deal with Hims & Hers resolves a legal feud and opens the telehealth channel to sell FDA‑approved Ozempic and Wegovy, which could shift patients away from compounded alternatives and support volume recovery. Patience Pays: Hims & Hers Surges on News of Novo Nordisk Deal
• Neutral Sentiment: India’s regulator warned against direct or surrogate advertising for weight‑loss drugs, which could constrain marketing strategies in a fast‑growing market but is not an immediate sales sanction. India warns drugmakers against direct or surrogate weight-loss drug and obesity ads
• Negative Sentiment: FDA issued a warning letter over failures in post‑marketing adverse event reporting tied to semaglutide (Ozempic/Wegovy), citing potential unreported serious events including deaths and a suicide — this raises regulatory risk and a near‑term compliance/oversight overhang. FDA issues warning to Novo Nordisk on unreported semaglutide safety events
• Negative Sentiment: Sell‑side and street pressure: TD Cowen downgraded NVO and other analysts flag that the pipeline may not blunt semaglutide loss‑of‑exclusivity (LOE) headwinds — reinforcing negative sentiment after guidance cuts. Novo Nordisk downgraded as pipeline ‘not poised to blunt semaglutide LOE’
• Negative Sentiment: Investor legal pressure: law firm Pomerantz announced an investigation into Novo Nordisk investors, signaling possible litigation risk and additional headline volatility. Pomerantz law firm investigates claims on behalf of investors of Novo Nordisk
• Negative Sentiment: Competitive pressure: Eli Lilly’s aggressive investments and programs (including China expansion and employer/coverage initiatives) keep the GLP‑1 market intensely competitive, which could pressure Novo’s pricing and market share over time. The Real Reason Eli Lilly Is Pouring $3 Billion Into China

About Novo Nordisk A/S

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.